И.Пүрэвдорж
Loading...
Товч нэр
И.Пүрэвдорж
Бүтэн нэр
Ичинхорлоо Пүрэвдорж
Латин нэр
Ichinkhorloo Purevdorj
Албан тушаал
Гэрээт багш
Боловсролын зэрэг
Доктор (Ph.D)
Харьяалал
ORCID
3 results
Now showing 1 - 3 of 3
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Use of Double Test Biomarkers to Predict Fetal Nuchal Translucency Thickness in the Diagnosis of Trisomy 21: A Compromise between Sensitivity and Specificity(Mongolian National University of Medical Sciences, 2018-09-25); ;Oyunchimeg Unshigbayar; ;Tsolmon BoldooErkhembulgan PurevObjectives: The aim of study is to determine the sensitivity and specificity of screening for fetal trisomy 21 in the first trimester of pregnancy using a combination of maternal serum biomarkers and ultrasonography. The objectives of this study were to first duplicate and confirm within the Mongolian population, the results of other similar studies. Our results corroborated closely with those of other studies and further allowed us to draw conclusions and recommendations unique to Mongolia. A second objective was to apply these results to everyday obstetric practices within Mongolia and advance the state of prenatal care for all Mongolian women. Methods: Obstetric History: The obstetric history was recorded, and serum biomarkers were measured in 415 pregnancies.The degree of risk for trisomy 21 and other fetal aneuploidy were calculated using maternal age, the results of maternal serum pregnancy-associated plasma protein-A, free beta human chorionic gonadotropin, and fetal nuchal translucency thickness. Grouping of Test Subjects: Using a cut-off risk estimate of 1 in 300, the women were grouped into positive and negative screening groups. Sensitivity and specificity of the screening method were calculated from the available data. Results: Sensitivity of the screening test for fetal trisomy 21 was 66.6% and for all fetal aneuploidy was 83%. Specificity of the screening test for fetal trisomy 21 was 87.5% and for all fetal aneuploidy was 97.8% and the false positive rate was 2.2%. Our results are consistent with the results obtained in other international studies. Conclusions: Our study is unique in that it is the first such scientific examination of mothers at risk for congenital abnormalities in Mongolia. This study provides empirical evidence that the combination of the double test, maternal age, and fetal nuchal translucency thickness is an effective prenatal screening method for fetal aneuploidy pregnancy outcomes in Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Taeniasis in Mongolia, 2002–2006(American Society of Tropical Medicine and Hygiene, 2007-08); ;Davaajav, Abmed ;Wandra, Toni ;Sandar, TsogtsaikhanScopus© Citations 19 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The genetic analysis of eight families with hemophilia B in Mongolia: Identification of two novel mutation(2024-09); ; ; ;Yoo, Ki-YoungBACKGROUND: This study aimed to conduct molecular diagnostics among individuals with hemophilia B (HB) and carriers of hemophilia in Mongolia. METHODS: Eight patients (six severe, two mild) with HB and their 12 female relatives were enrolled from eight families. Sanger sequence was performed for mutation identification. The questionnaire survey was conducted to evaluate carrier symptoms in female relatives. RESULTS: Two families had a history of HB. A total of five different variants (c.223C > T; c.344A > G; c.464G > C; c.187_188del; and c.1314_1314delA) were identified in six patients with severe HB. Of these, two (c.187_188del and c.1314_1314delA) were novel. No variant in the entire F9 was found in two patients with mild HB. Nonsense c.223C > T (p.Arg75*) mutation was detected in two unrelated patients. Carrier testing identified five mothers as carriers, while one younger sister was a non-carrier. The carrier status of six female relatives of the two mild patients remained undetermined. By questionnaire survey, only one of the five genetically identified carriers displayed noticeable symptoms of being a carrier. CONCLUSION: The novel variants c.187_188del and c.1314_1314delA can cause severe hemophilia B. This study did not observe a significant association between symptoms and carrier status in the five carriers.
